90,863 people (48.7%) completed a FOBT and 19,343 (10.4%) were excluded (high CRC risk or recent screening), so that adjusted participation rate was 54.3%. 77.3% of all completed FOBTs were provided by GPs and 15.5% were directly mailed. Participation ranged from 47.9% to 61.9% according to districts and was higher in women (56.6%) than in men (51.9%)(p<0.01). FOBT positivity rate was 3.3%. To date 2,595 colonoscopies were performed (84% of all positive FOBTs). Cecal intubation rate was 94.4%. Polyps were present in 45.2% of the colonoscopies and were adenomatous in 81.6% of cases. 1,746 adenomas were detected, 58.2% of them were sessile, 6.2% were flat, 4% were serrated and 26.5% had villous component. Their size was > = 20 mm in 16% of cases and from 10 to 19 mm in 26.1%. High grade dysplasia was present in 32.2% of adenomas, in situ carcinoma in 4.3% and invasive carcinoma in 2.2%. 95.2% of the adenomas were removed endoscopically. The positive predictive value was 10.3% for CRC, 21% for advanced adenomas and 42.6% for neoplasia (women 31.0%, men 52.2%). Detection rates for neoplasia and CRC were 12.2 and 2.9 per 1,000 people screened. 266 CRC were detected, 27.2% of them were in situ. 50% of invasive CRC were stage I and 23.4% stage II. The rate of proximal advanced neoplasia increased with age (16.5% below 65 years, 25.4% after) but didn’t differ with gender. A screening strategy with flexible sigmoidoscopy would have missed 21.4% of people with advanced neoplasia, without significant difference according to age and gender. The overall cost of this biennial screening program (without the fees related to colonoscopies) was €2.3 million: fixed cost was €1.6 million (4.3€ a year per eligible person) and variable cost €0.7 million (3.3€ per screened person). The overall cost per screened person was 26€ and the cost to find either an advanced adenoma or an early-stage CRC (in situ or stage I) was 3650€.